KembaraXtra-Medicine- Angular Cheilitis


Basic Information
Angular cheilitis is a chronic, reactive inflammatory disorder at the corners of the mouth (oral commissures). It presents with atrophy, erythema, scaling, fissures (rhagades), crusting, and sometimes exudate. In many cases it reflects an infectious process, commonly opportunistic fungal and/or bacterial infection, and severity can range from mild irritation to painful cracking and ulceration.


Synonyms
Angular cheilosis; Rhagades; Commissural cheilitis; Perlèche (Perleche); Angular stomatitis.


ICD-10-CM Codes
K13.0 Diseases of lips; B37.83 Candidal cheilitis.


Epidemiology and Demographics
Incidence is unknown. It is suspected to account for about 0.5% to 5% of adult lip infections. It has a predilection for older adults, especially in association with denture use, and peak occurrence is in advanced age. No genetic correlation has been identified.


Risk Factors
Risk factors include xerostomia (dry mouth), nutritional deficiencies (notably B vitamins and iron), HIV infection, immunosuppression, and chronic irritation or moisture at the commissures. Common mechanical and behavioral contributors include lip licking, drooling, oral hardware, and dentures. Medications that cause dry mouth or hypersalivation can contribute and may lead to bilateral involvement.


Physical Findings and Clinical Presentation
Most cases involve both corners of the mouth. Early findings often include erythema and swelling at the commissures. Over time, linear fissures (rhagades) develop and may crack, crust, or ulcerate. With ongoing inflammation, skin thickening can occur. Disease may be limited to the lip mucosa or extend beyond the vermillion border onto the adjacent facial skin.


Etiology
Infectious causes are common and include Candida species, Staphylococcus aureus, beta-hemolytic Streptococcus species, or mixed (polymicrobial) infection. A frequent noninfectious driver is chronic saliva irritation pooling at the mouth corners, especially with overclosure of the jaw—classically seen in edentulous patients and denture wearers. Any condition that promotes chronic moisture or irritation (lip licking, drooling, oral fixation habits) can trigger or perpetuate the condition. Nutritional deficiencies—especially iron, B vitamins, and zinc—are associated. Immunosuppression (e.g., diabetes mellitus, HIV) increases susceptibility to subacute infection. Medication-related xerostomia or hypersalivation can also predispose to disease.


Diagnosis
Diagnosis is primarily clinical, based on appearance and a careful review of medical history, denture/oral appliance use, habits (lip licking, drooling), and medications.


Differential Diagnosis
Consider oral candidiasis with commissural involvement, S. aureus infection/impetigo, contact dermatitis, and angular herpes simplex.


Workup
Most patients require only clinical assessment. When infection is suspected or disease is recurrent/refractory, bacterial and fungal cultures can help identify the causative organism(s). When systemic contributors are possible, routine laboratory evaluation may include CBC, HIV testing, basic metabolic panel, and assessment for nutritional deficiencies such as iron studies, folate, and vitamin B12.


Laboratory Tests
When indicated, obtain bacterial and fungal cultures. Additional labs may include CBC, HIV, basic metabolic panel, iron, folate, and vitamin B12, especially if risk factors, recurrence, or poor response to therapy suggests underlying systemic disease.


Imaging Studies
None are required.


Treatment
Treatment depends on identifying and correcting the underlying cause(s). Because angular cheilitis is common in denture wearers, ensuring proper denture fit and excellent oral/denture hygiene is essential. Smoking and tobacco cessation are part of good oral hygiene and support healing. Topical antifungal therapy is a cornerstone because Candida albicans is implicated in more than half of cases. If bacterial pathogens such as S. aureus or streptococci are involved, targeted therapy is needed. If symptoms persist despite appropriate treatment, further evaluation is warranted to look for systemic or nutritional causes.


Nonpharmacologic Therapy
Prevention and management rely heavily on denture hygiene and regular cleaning; over-the-counter alcohol- or bleach-based denture-cleaning solutions are commonly used. If deep overclosure or marked skin “lag” at the mouth corners contributes, procedural options such as surgery or collagen/filler injections may help correct the mechanical problem. Petrolatum (petroleum jelly) can be used as a protective barrier and for prevention.


Acute General Treatment
Because inflammation is central, topical corticosteroids are commonly used. If S. aureus is implicated, topical mupirocin or fusidic acid may be used. For suspected or confirmed Candida involvement, topical antifungals such as clotrimazole or ketoconazole are commonly used.


Chronic Management
When lab work identifies nutritional deficiency, supplementation with iron, B vitamins, and/or folate can improve or resolve disease. Persistent cases may require addressing denture alignment and vertical dimension, sometimes involving dental refitting and, in selected cases, surgical repair. Treatment-refractory cases should prompt reassessment for systemic causes and reconsideration of diagnosis.


Disposition
Outpatient evaluation and treatment are appropriate in most cases.


Referral
Dermatology referral is reasonable for refractory or recurrent angular cheilitis.


Pearls and Considerations
Determining the etiology is the key step because it directs therapy and prevents recurrence. Prevention focuses on eliminating organisms from reservoirs and correcting mechanical factors. Evaluate for denture stomatitis, oral candidiasis, and possible nasal staphylococcal colonization when recurrences occur. Dentures should be removed nightly and thoroughly cleaned before reinsertion in the morning. Replacing ill-fitting dentures can restore facial contours and increase the vertical dimension of the jaws, reducing saliva pooling. In some patients, fillers injected into the commissures can lessen mechanical contributors and reduce recurrence.

KembaraXtra-Medicine- Angioedema


Basic Information
Urticaria and angioedema are mucocutaneous swellings that occur after release of vasoactive mediators. Urticaria affects the superficial dermis and produces wheals, whereas angioedema results from a transient increase in vascular permeability in mucosal/submucosal or dermal/subcutaneous tissues, leading to deeper tissue swelling.


Synonyms
Angioneurotic edema; Hereditary angioedema (HAE).


ICD-10-CM Codes
T78.3 Angioedema; D84.1 Angioedema, hereditary.


Epidemiology and Demographics
Urticaria and angioedema together have an incidence of about 100 to 3000 per 100,000 persons, and approximately 7.4% of the general population will experience angioedema alone. Around 25% of people will have urticaria and/or angioedema at some point in life. Hereditary angioedema occurs in about 1 in 50,000 persons. African Americans have higher rates of ACE inhibitor–induced angioedema. Angioedema occurs more often in women than men and commonly begins after adolescence, often in the third decade of life. Angioedema can occur with urticaria (about 40%) or alone (about 20%); the remaining ~40% have urticaria alone. For HAE due to C1 inhibitor problems, mean onset is 8–12 years and it rarely presents before age 1.


Physical Findings and Clinical Presentation
Angioedema may be acute or chronic. Acute angioedema is defined as symptoms lasting up to 6 weeks, while chronic angioedema lasts longer than 6 weeks. Typical swelling is nonpruritic, nonpitting, burning, and occasionally painful, involving deep skin layers or submucosal membranes. It is poorly demarcated and most often affects eyelids, lips, tongue, and extremities. It can involve the upper airway and cause respiratory distress, and it can involve the gastrointestinal tract, producing cyclic abdominal pain, nausea, vomiting, and diarrhea. Symptoms generally resolve slowly over hours to a few days.


Etiology and Pathophysiology
Angioedema (with or without urticaria) is broadly classified as histaminergic (mast cell–mediated or idiopathic) or bradykinin-mediated (such as hereditary forms). It is primarily triggered by immune activation with mediator release (histamine, serotonin, bradykinin), causing postcapillary venule inflammation, vascular leakage, and edema in deeper dermis/subcutaneous tissues. Mechanisms can be immunologic or nonimmunologic. IgE-mediated angioedema may follow exposure to foods (milk, eggs, peanuts, shellfish) or drugs (beta-lactam antibiotics, aspirin, NSAIDs, phenytoin, sulfonamide antibiotics, recombinant tissue plasminogen activator). Complement/immune-complex–mediated pathways can activate mast cells and may present as serum sickness.


Hereditary angioedema is subdivided into HAE type 1 (C1 inhibitor deficiency), HAE type 2 (C1 inhibitor dysfunction), and HAE with normal C1 inhibitor function (HAE nC1-INH). HAE-1 and HAE-2 are commonly due to autosomal dominant SERPING1 mutations affecting C1 esterase inhibitor (C1-INH). C1-INH inhibits plasma kallikrein; without adequate inhibition, kallikrein promotes bradykinin generation. Bradykinin is a potent vasodilator that increases capillary permeability and activates pain receptors, so excess bradykinin leads to angioedema. HAE-1 and HAE-2 are typically associated with low C4 due to complement activation, because C1 inhibitor is a major regulatory protein in the complement cascade.


Acquired angioedema is often linked to underlying disease—most commonly B-cell lymphoproliferative disorders—or may occur from autoantibodies against C1 inhibitor. Other triggers include infections (herpes simplex, hepatitis B, Coxsackie A/B, Streptococcus, Candida, Ascaris, Strongyloides), insect bites or stings, stress, physical factors (cold, exercise, pressure, vibration), connective tissue diseases (systemic lupus erythematosus, Henoch–Schönlein purpura), and idiopathic causes. ACE inhibitors can increase kinin activity and precipitate angioedema. Other medication triggers include antibiotics (beta-lactams, quinolones), opiates, and muscle relaxants (succinylcholine).


Diagnosis
A careful history and physical examination usually establish the diagnosis. Extensive laboratory testing is often of limited value.


Differential Diagnosis
Consider anaphylaxis, contact dermatitis, cellulitis, lymphedema, arthropod bite, hypothyroidism, atopic dermatitis, mastocytosis, granulomatous cheilitis, bullous pemphigoid, urticaria pigmentosa, erythema multiforme, epiglottitis, peritonsillar abscess, parasitic infection, and superior vena cava syndrome.


Workup
A broad workup to identify a cause is frequently unrevealing (about 40%). Testing is guided by the clinical history and exam. Basic tests such as CBC, ESR, and urinalysis may help in initial evaluation. Serum total tryptase can help confirm mast cell–mediated anaphylaxis. C4 is usually low in acquired and hereditary angioedema that occurs without urticaria; when C4 is low, measure C1-INH level and functional activity. Rarely, HAE may present with normal C4 but reduced C1-INH. If food allergy is suspected, skin prick testing and/or in vitro specific IgE testing (e.g., ImmunoCAP) may be used. Skin biopsy is generally reserved for chronic angioedema that is refractory to corticosteroids. Stool ova and parasite testing may be considered when parasitic infection is a concern.


Treatment: Nonpharmacologic Therapy
Remove or eliminate the offending agent when possible and avoid known triggers such as cold, stress, and culprit medications (especially ACE inhibitors). Cold compresses can be applied to affected areas for symptomatic relief.


Acute General Treatment
Life-threatening angioedema involving the larynx is treated urgently, although it is important to recognize that bradykinin-mediated angioedema responds minimally to these standard allergic-reaction medications. Typical emergency medications include subcutaneous epinephrine 0.3 mg (1:1000), an H1 antihistamine such as diphenhydramine 25–50 mg IV/IM or cetirizine 10 mg (listed as IV in the source), an H2 blocker such as cimetidine 300 mg IV or famotidine 20 mg IV, and methylprednisolone 125 mg IV.


For mast cell–mediated, nonhereditary angioedema, maintenance therapy centers on H1 antihistamines: cetirizine 10 mg daily (sometimes up to 4× FDA-approved dose), fexofenadine 180 mg daily (sometimes up to 4× dose), hydroxyzine 10–25 mg every 6 hours, or diphenhydramine 25–50 mg every 6 hours. H2 antihistamines can be added (cimetidine 400 mg twice daily or famotidine 20 mg twice daily). Doxepin 25–50 mg at bedtime can be used as an adjunct. Corticosteroids may be used for symptomatic relief in refractory acute cases. Antihistamines are ineffective for hereditary angioedema attacks.


Acute HAE attacks due to C1 inhibitor deficiency respond well to targeted therapies. Approved abortive options include plasma-derived C1 inhibitor concentrate (Berinert), icatibant (Firazyr), a bradykinin B2 receptor antagonist, and ecallantide (Kalbitor), a kallikrein inhibitor. Purified plasma-derived C1-INH replacement is considered effective and safe for acute attacks.


Chronic Treatment
Chronic histaminergic angioedema is treated similarly to acute management with H1 antihistamines, addition of H2 antihistamines as needed, and corticosteroids reserved for refractory cases. A regimen cited for refractory cases is prednisone 1 mg/kg/day for 5 days followed by a 7-day taper. Omalizumab (anti-IgE monoclonal antibody) has shown benefit in cases refractory to antihistamines, though it is not FDA-approved specifically for this indication.


For hereditary angioedema long-term prophylaxis, older options include androgens (danazol, stanozolol, oxandrolone, methyltestosterone) and antifibrinolytics, but adverse effects can be significant. Intravenous plasma-derived C1 inhibitors (Cinryze, Berinert) are safe and effective for patients with frequent or severe attacks, though cost may limit access. A twice-weekly subcutaneous C1-INH formulation (Haegarda/CSL830) is FDA-approved for HAE-1 and HAE-2. Lanadelumab and berotralstat (kallikrein inhibitors) have FDA approval for prophylaxis of HAE. In a phase 2 trial, donidalorsen (an antisense oligonucleotide that reduces plasma prekallikrein production) lowered attack rates compared with placebo.


Disposition
More than 85% of patients with nonhereditary acute angioedema achieve symptomatic relief with antihistamines. In chronic nonhereditary angioedema, antihistamines remain the mainstay, and systemic steroids should be reserved for severe or refractory cases. Some patients have recurrence after completing treatment. Chronic angioedema can persist for months to years and may be longer in hereditary angioedema.


Referral
Referral to a dermatologist and/or allergist is recommended for chronic angioedema, hereditary angioedema, and recurrent angioedema. HAE is potentially life-threatening and should be managed by an allergist.


Pearls and Considerations
ACE inhibitor–induced angioedema can occur months or even years after starting the drug. ARB-induced angioedema has been reported, though risk is substantially lower than with ACE inhibitors. About 10% of patients with recurrent angioedema had ACE inhibitor exposure, with a median duration of 1 year before symptoms began. Reported incidence rates per 1000 person-years are approximately 4.38 for ACE inhibitors, 1.66 for ARBs, and notably high for the direct renin inhibitor aliskiren (about 4.67).


Comments
Finding a clear cause is often difficult and can be frustrating. Chronic angioedema is rarely due to an allergic reaction, unlike many acute cases. Hereditary angioedema requires specialized care because of its life-threatening potential.

KembaraXtra-Medicine- Angina Pectoris


Basic Information
Angina pectoris is a clinical syndrome of discomfort in the chest, jaw, shoulder, back, or arm caused by myocardial ischemia. Most commonly it is related to atherosclerotic (atheromatous) plaque in one or more large epicardial coronary arteries, but ischemia can also occur without obstructive coronary artery disease. Nonobstructive causes include uncontrolled hypertension, microvascular disease, valvular heart disease, hypertrophic cardiomyopathy, coronary spasm, and endothelial dysfunction. In general, any condition that creates an imbalance between myocardial oxygen supply and demand can produce an angina syndrome.


Classification of Angina
Chronic stable angina (also termed stable ischemic heart disease or chronic coronary artery disease) is typically predictable and follows a precipitating event such as climbing stairs, sexual intercourse, a heavy meal, emotional stress, or cold weather. Episodes usually resemble prior attacks in severity and are relieved by rest or the patient’s customary dose of sublingual nitroglycerin. It is usually caused by fixed coronary obstruction from atherosclerosis, commonly with one or more major coronary stenoses, often >70%. Unstable angina includes rest angina, recent-onset angina, and crescendo angina and is addressed under acute coronary syndrome. Rest angina occurs at rest, is usually prolonged (>20 minutes), and occurs within 1 week of presentation. Recent-onset angina is angina of at least Canadian Cardiovascular Society (CCS) Class III severity beginning within the past 2 months. Crescendo angina is previously diagnosed angina that becomes more frequent, lasts longer, or occurs at a lower threshold, defined as worsening by more than one CCS class within 2 months to at least CCS Class III severity.


Prinzmetal (variant) angina occurs at rest, is commonly triggered after cold exposure, and tends to be cyclical. It is associated with episodic ST-segment elevations on ECG and is due to coronary artery spasm with or without superimposed coronary artery disease; these patients are more prone to ventricular arrhythmias. Microvascular angina (syndrome X) refers to patients with angina symptoms, a positive exercise test, normal coronary angiograms, and no coronary spasm. In this condition, defective endothelium-dependent dilation in the coronary microcirculation contributes to abnormal regulation of myocardial perfusion and ischemic symptoms. Patients with chest pain and normal or nonobstructive coronary angiograms are predominantly women, and prognosis may be less benign than often assumed, with about a 2% risk of death or myocardial infarction at 30 days.


Refractory angina describes patients who, despite optimal medical therapy using at least maximal tolerated doses of two antianginal medications (plus aspirin and intensive risk-factor modification such as smoking cessation and tight control of hypertension, diabetes, and hyperlipidemia), continue to have angina along with objective evidence of ischemia. Other causes of angina syndromes include angina due to aortic stenosis, idiopathic hypertrophic subaortic stenosis, and cocaine-induced coronary vasoconstriction.


Functional Classification (Canadian Cardiovascular Society, CCS)
Class I: ordinary physical activity (walking, climbing stairs) does not cause angina; symptoms occur only with strenuous, rapid, or prolonged exertion at work or recreation. Class II: slight limitation of ordinary activity; angina occurs with walking or climbing stairs rapidly, walking uphill, activity after meals, exposure to cold or wind, emotional stress, or during the first few hours after awakening; angina occurs when walking more than two level blocks or climbing more than one flight of ordinary stairs at a normal pace in normal conditions. Class III: marked limitation of ordinary physical activity; angina occurs with walking one to two level blocks or climbing one flight of stairs in normal conditions at a normal pace. Class IV: inability to carry on any physical activity without discomfort; anginal symptoms may be present at rest.


ICD-10-CM Codes
I20.1 Angina pectoris with documented spasm; I20.8 Other forms of angina pectoris; I20.9 Angina pectoris, unspecified. I25.110 Atherosclerotic heart disease of native coronary artery with unstable angina pectoris; I25.111 Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm; I25.118 Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris; I25.119 Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris. I25.700 Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris; I25.790 Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris; I25.791 Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm; I25.798 Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris; I25.799 Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris.


Epidemiology and Demographics
Approximately one in three adults in the United States (about 81 million) has some form of cardiovascular disease. Based on NHANES 2007–2010, an estimated 15.4 million people have coronary heart disease, and about 7.8 million have angina. Angina is most common in middle-aged and elderly men. Among persons aged 60–79 years, roughly 25% of men and 16% of women have coronary heart disease; among those older than 80 years, the figures rise to about 37% for men and 23% for women. After menopause, the incidence of coronary heart disease and angina in women becomes similar to that in men. Even with improving survival over time, stable ischemic heart disease remains the leading cause of death in men and women (about 27% of deaths). Angina is the initial manifestation of ischemic heart disease in about 50% of cases, and about half of patients who present with acute coronary syndrome report preceding angina. Older population-based studies (Olmstead County, MN and Framingham, MA) reported an annual myocardial infarction rate of about 3%–3.5% per year among patients with symptomatic angina. Within 12 months of stable angina diagnosis, about 10%–20% progress to myocardial infarction or unstable angina.


Physical Findings and Clinical Presentation
Evaluating chest pain requires attention to quality, location, severity, duration, radiation, associated symptoms, provoking factors, and relieving factors. Anginal pain is often described as squeezing, griplike, suffocating, or heavy; it is rarely sharp or stabbing and typically does not change with position or respiration. The classic Levine sign is a clenched fist placed over the precordium. Many patients describe angina not as “pain” but as tightness, pressure, or discomfort. Atypical presentations are more common in women and older adults and may include nausea, vomiting, midepigastric discomfort, sharp (atypical) chest pain, dizziness, or syncope. Ischemic discomfort lasting longer than 20 minutes should raise concern for acute coronary syndrome. Women are more likely than men to report atypical chest pain or discomfort (reported by 65% in the WISE study). Elderly patients and those with diabetes may present with non–chest pain symptoms such as dyspnea, fatigue, or diaphoresis.


Etiology and Risk Factors
Key risk factors include advanced age, male sex, and genetic predisposition such as a family history of premature coronary artery disease in first-degree relatives (men <55 years, women <65 years). smoking increases the risk of first myocardial infarction nearly threefold. other major risks include hypertension, hyperlipidemia, impaired glucose tolerance or diabetes mellitus, prior stroke peripheral arterial disease, chronic kidney metabolic syndrome, physical inactivity, and obesity (bmi>30% over ideal). Higher childhood BMI is also associated with increased adult coronary heart disease risk.


Several conditions increase myocardial oxygen demand, including hyperthermia (especially with volume contraction), hyperthyroidism, and cocaine or methamphetamine use. Cocaine is used regularly by more than 5 million Americans and leads to over 64,000 emergency department evaluations yearly to rule out myocardial ischemia; it causes sympathomimetic toxicity, increases oxygen demand, induces coronary vasospasm, and can cause infarction in young patients, while long-term use accelerates stable ischemic heart disease. Severe uncontrolled hypertension increases myocardial oxygen demand and reduces subendocardial perfusion by increasing left ventricular wall tension; hypertrophic cardiomyopathy and aortic stenosis can produce even more severe hypertrophy and wall tension. Ventricular or supraventricular tachycardias can also raise oxygen demand and may require ambulatory monitoring for diagnosis.


Reduced oxygen supply can trigger angina as well. Anemia may cause angina when hemoglobin falls below about 9 g/dL, and ST–T changes (depression or inversion) can occur at hemoglobin levels below about 7 g/dL. Hypoxemia from pulmonary disease such as pneumonia, asthma, COPD, pulmonary hypertension, interstitial fibrosis, or obstructive sleep apnea can precipitate angina. Additional associated conditions and exposures include polycythemia, leukemia, thrombocytosis, hypergammaglobulinemia, oral contraceptive or hormone replacement therapy use, coronary artery calcium (linked to higher MI risk), long-term NSAID use, and traffic-related air pollution (dilute diesel exhaust), which promotes ischemia and adverse cardiovascular events. Low serum folate (needed to convert homocysteine to methionine) is associated with increased fatal coronary heart disease risk; hyperhomocysteinemia damages endothelium and promotes arterial smooth muscle proliferation and is an independent risk factor for coronary events, particularly in type 2 diabetes. Elevated high-sensitivity C-reactive protein (cardio-CRP) reflects systemic inflammation and is linked to accelerated atherosclerosis. Other noted associations include depression, vasculitis, elevated lipoprotein-associated phospholipase A2, elevated fibrinogen, low red blood cell glutathione peroxidase-1 activity, and prior radiation therapy.


Diagnosis: Differential Diagnosis
Nonischemic cardiovascular causes include aortic dissection and pericarditis. Pulmonary causes include pulmonary embolism, pneumothorax, pneumonia, and pleuritis. Gastrointestinal causes include esophageal disorders (esophagitis, spasm, reflux), biliary colic, cholecystitis, choledocholithiasis, cholangitis, peptic ulcer disease, pancreatitis, and other upper GI pathology. Chest wall causes include costochondritis, fibrositis, rib fracture, sternoclavicular arthritis, and herpes zoster before rash onset. Psychiatric causes include anxiety disorders, hyperventilation, panic disorder, primary anxiety, affective disorders (including depression), somatoform disorders, and thought disorders such as fixed delusions.


Workup and Clinical Risk Assessment
In patients with chest pain, estimate the probability of coronary artery disease based on age, sex, cardiovascular risk factors, and pain characteristics. History is the most important diagnostic element: exertional chest or left arm discomfort relieved by rest in a patient with risk factors strongly suggests coronary disease. Chest pain is categorized as typical angina, atypical angina, or noncardiac chest pain. Typical (definite) angina includes all three: substernal discomfort with characteristic quality and duration, provoked by exertion or emotional stress, and relieved by rest and/or sublingual nitroglycerin. Atypical (probable) angina has two of these features. Noncardiac chest pain has one or none.


Physical examination may be normal, but findings such as hypertension, arcus senilis, xanthelasma, carotid or peripheral bruits, and a prominent S4 increase suspicion for coronary artery disease. A mitral regurgitation murmur may indicate ischemic cardiomyopathy or transient ischemia, while murmurs of hypertrophic cardiomyopathy or aortic stenosis suggest non-CAD causes of angina. The overall evaluation aims to identify high-risk coronary disease while minimizing resource use. A practical approach considers (1) coronary risk assessment using classic risk factors, (2) functional capacity and stress test results, (3) left and right ventricular function, and (4) coronary anatomy, recognizing not every patient needs every modality. Patients without known coronary artery disease are typically stratified into low, intermediate, or high pretest probability after considering comorbidities and atherosclerotic risk; functional capacity and stress testing (exercise tolerance test, exercise testing with myocardial perfusion imaging, or stress echocardiography) are emphasized for low-to-intermediate probability groups. Exercise testing is preferred when feasible. Stress results help estimate annual mortality risk: <1% low risk, 1%–3% intermediate and>3% high risk.


Laboratory Tests and ECG/Imaging Basics
Screen for hypertension, diabetes, and hyperlipidemia per routine guidelines. Obtain an ECG during pain and when the patient is symptom-free; a normal resting ECG can occur in stable ischemic heart disease, and a small percentage of acute MI patients may have a normal or nondiagnostic ECG. Chest x-ray (PA and lateral) is considered when symptoms suggest heart failure, pericardial disease, or aortic aneurysm/dissection. High-sensitivity CRP (cardio-CRP) is a moderate predictor of coronary disease and adds prognostic value beyond the Framingham risk score.


Exercise Testing and Stress Imaging
Exercise testing is used for diagnosis and prognosis and provides important prognostic information via exercise performance and hemodynamic response. It is most useful in intermediate-likelihood patients because low-likelihood patients can have false positives and high-likelihood patients can have false negatives. The treadmill test is contraindicated when baseline ECG abnormalities make interpretation unreliable, including ST depression >0.5 mm, Wolff-Parkinson-White syndrome, left bundle branch block, or pacemaker rhythm. If baseline ECG abnormalities prevent interpretation, use stress echocardiography or myocardial perfusion imaging. Stress echocardiography tends to have higher specificity and lower cost, whereas radionuclide perfusion imaging has higher sensitivity (notably for single-vessel disease) and higher technical success. If the patient cannot exercise adequately, pharmacologic stress testing (e.g., dobutamine, adenosine, regadenoson) can be paired with these imaging modalities.


Risk Stratification From Noninvasive Testing
High risk (>3% annual risk of death or MI) includes severe resting LV dysfunction (LVEF <35%) not explained by noncoronary causes; resting perfusion abnormalities involving ≥10% of myocardium without prior mi; high-risk stress ecg findings such as ≥2 mm st depression at low workload or persisting into recovery, exercise-induced elevation, ventricular tachycardia />ibrillation; severe stress-induced LV dysfunction (peak exercise LVEF <45% or lvef drop ≥10%); stress-induced perfusion abnormalities involving ≥10% of myocardium multiple vascular territories; lv dilation; inducible wall motion abnormality>2 segments or two coronary beds; wall motion abnormality at low-dose dobutamine (≤10 mg/kg/min) or low heart rate (<120 bpm); and multivessel obstructive cad (≥70%) or left main stenosis (≥50%) on coronary cta.< />pan>


Intermediate risk (1%–3% annual risk) includes mild-to-moderate resting LV dysfunction (LVEF 35%–49%); resting perfusion abnormalities involving 5%–9.9% without prior MI; ≥1 mm ST depression with exertional symptoms; stress perfusion abnormalities involving 5%–9.9% or one vascular territory without LV dilation; small wall motion abnormality involving 1–2 segments and one coronary bed; and single-vessel CAD ≥70% or moderate stenosis (50%–69%) in ≥2 arteries on coronary CTA. Low risk (<1% annual risk) includes a low-risk treadmill score (≥5) or no new st changes exercise-induced chest pain at maximal exercise; normal small perfusion defect involving <5% of myocardium; stress change in limited resting wall motion abnormalities with stress; and coronary stenosis>50% on coronary CTA (noting these “low-risk” findings may not indicate truly low risk if a high-risk treadmill score or severe resting LV dysfunction is present). Coronary artery calcium assessment may also contribute to risk stratification.


A useful predictor in stable angina is the Duke treadmill score, combining exercise time/METS (Bruce protocol), ST-segment depression in millimeters, and an angina index; favorable scores (>5) are associated with >97% five-year survival independent of coronary anatomy and LV function.


Echocardiography, Coronary CTA, Calcium Scoring, Cardiac MRI, and Invasive Angiography
Echocardiography is indicated when murmurs suggest aortic stenosis, hypertrophic cardiomyopathy, mitral regurgitation, or mitral valve prolapse, and in patients with prior MI, pathologic Q waves, complex ventricular arrhythmias, heart failure, hypertension, diabetes, or abnormal ECG. Coronary CT angiography (CCTA) can detect subclinical CAD in asymptomatic patients with intermediate 10-year Framingham risk (10%–20%) and is recommended by 2021 ACC/AHA/ASE chest pain guidelines as a front-line imaging modality for stable angina. Studies comparing CCTA to invasive coronary angiography in stable angina show similar outcomes but fewer procedural complications and fewer invasive angiograms with an initial CCTA strategy. CCTA evaluates coronary calcium, lumen, and vessel wall; it can be first-line for risk assessment when a patient cannot exercise adequately, can clarify indeterminate functional tests, and can assess bypass graft or large stent patency (>3 mm). Cost and radiation limit routine broad use. CCTA has high negative predictive value to rule out severe CAD during ED chest pain evaluation (ROMICAT-II), and the SCOT-HEART trial (2018) showed coronary CTA lowered nonfatal MI risk compared with standard care alone in stable angina. Myocardial perfusion imaging and noninvasive fractional flow reserve can also be derived from cardiac CTA in selected settings.


Coronary artery calcium scoring provides strong predictive value beyond standard risk factors in low-to-intermediate pretest probability patients; a score <100 suggests low risk, while>400 suggests high risk. Cardiac MRI, beyond diagnosing arrhythmogenic right ventricular dysplasia, can assess perfusion, viability, and function in patients unable to exercise, though further cost-effectiveness data are needed in ischemic cardiomyopathy. Invasive coronary angiography remains the gold standard to define clinically significant CAD and is used to map location and extent of disease, especially in patients being considered for revascularization (CABG or angioplasty).


Treatment Overview: Core Strategies
Management involves five overlapping strategies: patient education and shared decision-making; management of comorbid conditions that worsen stable ischemic heart disease; aggressive modification of preventable risk factors (smoking cessation, weight loss in obesity, regular aerobic exercise 30–60 minutes/day for 5 days/week, folate deficiency correction, limiting saturated fat to <7% of calories and trans fats to <1%, low-sodium diet <2 g />ay, and emphasizing medication adherence); evidence-based pharmacologic therapy to improve symptoms and survival; and appropriate revascularization for selected patients to improve survival and long-term outcomes.


Pharmacologic Therapy (Prevention of MI/Death and Symptom Control)
Aspirin reduces cardiovascular mortality and morbidity by about 20%–25% in CAD; the usual dose is 75–162 mg/day if no contraindication. It inhibits cyclooxygenase and thromboxane A2 and reduces adverse cardiovascular events; patients intolerant of aspirin may use clopidogrel or undergo aspirin desensitization. Clopidogrel irreversibly blocks the P2Y12 ADP receptor, reducing platelet activation and aggregation; it can be used alone for aspirin intolerance or combined with aspirin in high-risk stable ischemic heart disease patients with low bleeding risk; dose is 75 mg/day. Ticagrelor (PEGASUS-TIMI 54) reduced death, cardiovascular MI, or stroke in patients after one year post-MI but increases bleeding risk versus placebo. Dipyridamole is not recommended as antiplatelet therapy in stable ischemic heart disease.


Beta-blockers are first-line for stable angina and have proven benefits in preventing MI and death. They reduce myocardial oxygen demand by lowering heart rate, blood pressure, AV nodal conduction, and contractility, raising the ischemic threshold and decreasing angina frequency. Doses are generally adjusted to achieve a resting heart rate of 55–60 bpm. Beta-blockers are recommended for at least 2–3 years after MI and lifelong for patients with LVEF <40% with heart failure or prior mi.< />pan>


Nitrates cause venodilation and vascular smooth muscle relaxation, decreasing preload (and myocardial oxygen consumption) and reducing resistance across obstructed segments, while redistributing coronary flow by augmenting collateral circulation and lowering LV diastolic pressure; they also have antithrombotic and antiplatelet effects. Sublingual nitroglycerin or spray should be prescribed for immediate angina relief in stable ischemic heart disease. Nitrate tolerance can be minimized with a daily nitrate-free interval (e.g., omit bedtime oral isosorbide dinitrate or use a 12-hour on/12-hour off transdermal schedule). Nitrates are relatively contraindicated in hypertrophic obstructive cardiomyopathy and should be avoided in severe aortic stenosis. They must not be used within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil because of hypotension risk.


Calcium channel blockers improve oxygen supply by lowering coronary resistance and increasing arterial flow and reduce demand by lowering contractility and systemic vascular resistance; however, they have no proven mortality benefit in stable ischemic heart disease. They are first-line when beta-blockers are contraindicated, are key in coronary spasm, and are effective in microvascular angina. All classes reduce angina episodes, increase exercise duration, and reduce nitroglycerin use in effort-induced angina, but short-acting agents should be avoided. Nondihydropyridine calcium channel blockers should generally be avoided in systolic heart failure due to negative inotropy.


Ranolazine (studied in MARISA, CARISA, RAN080, ERICA; total ~1737 patients) inhibits the late inward sodium current, indirectly reducing sodium-dependent calcium influx during ischemia and improving diastolic tension and oxygen consumption. Its antianginal effects do not depend on heart rate or blood pressure reduction and it is used for chronic angina inadequately controlled by other agents, either as an alternative or in combination. It can prolong the QT interval, and low doses of diltiazem or verapamil should be used if combined.


ACE inhibitors may reduce LV/vascular hypertrophy, slow atherosclerosis progression, reduce plaque rupture/thrombosis risk, and improve hemodynamics and oxygen balance. They reduce cardiovascular death, MI, and stroke in at-risk patients or those with vascular disease, and are indicated in stable ischemic heart disease patients with hypertension, diabetes, LVEF <40%, or chronic kidney disease. arbs are alternatives for ace-intolerant patients who qualify.< />pan>


High-intensity statins are recommended for all patients with CAD. The ACC has recommended an LDL goal <70 mg />L for secondary prevention (no LDL goal for primary prevention). PCSK9 inhibitors (alirocumab, evolocumab) are approved for heterozygous familial hypercholesterolemia and are considered in very-high-risk atherosclerotic cardiovascular disease patients not at LDL goal despite high-intensity statin plus ezetimibe; ezetimibe should generally be tried before PCSK9 inhibitors due to cost. Inclisiran, evinacumab, and bempedoic acid are reasonable nonstatin options for patients unable to tolerate statins or reach LDL targets. Annual influenza vaccination is recommended in stable ischemic heart disease to reduce mortality, morbidity, and hospitalization. In type 2 diabetes, major trials (EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, CREDENCE) show SGLT2 inhibitors reduce cardiovascular events.


Newer and Adjunct Modalities for Chronic Stable Angina
Despite progress with PCI and CABG, some patients need additional therapies for symptom relief and quality of life, especially those with diffuse CAD unsuitable for revascularization, multiple prior PCIs/CABG, lack of bypass conduits, severe LV systolic dysfunction after revascularization, or comorbidities making procedures high risk. Pharmacologic agents explored as adjuncts to standard therapy (nitrates, beta-blockers, calcium channel blockers, ranolazine) include high-dose statins, trimetazidine, perhexiline, nicorandil, allopurinol, ivabradine, fasudil, and testosterone. Experimental nonpharmacologic options include stem cell therapy, therapeutic angiogenesis, and mechanical therapies such as enhanced external counterpulsation, spinal cord stimulation, transmyocardial laser revascularization, and coronary sinus reducing devices.


In TACT, EDTA chelation infusions reduced a composite outcome (including mortality, recurrent MI, stroke, revascularization, or angina hospitalization), leading chelation therapy to be upgraded from Class III (not recommended) to Class IIb in 2014 stable ischemic heart disease guidelines. Allopurinol (xanthine oxidase inhibitor) at 600 mg daily for 6 weeks in a small crossover study of 65 heart failure patients increased median time to ST depression (232 to 393 seconds), but larger studies are needed before recommending it routinely. Testosterone may improve endothelial dysfunction and potentially angina, but safety concerns require more trials. EECP was assessed in MUST-EECP (139 outpatients randomized to 35 hours active EECP), showing it was well tolerated; exercise duration rose in both groups; active EECP increased time to 1-mm ST depression while inactive did not; and more active EECP patients had fewer angina episodes. Professional society updates state EECP may be considered for refractory angina. Treatments not shown to reduce cardiovascular risk or improve outcomes include estrogen therapy; vitamin C, vitamin E, beta-carotene supplementation; folate/B6/B12 therapy solely to lower homocysteine; chelation therapy (outside its limited guideline context); garlic; coenzyme Q10; selenium; and chromium.


Referral and Revascularization
Revascularization strategy is chosen to improve survival and/or symptoms and includes PCI (balloon angioplasty and stenting) or CABG. While PCI is clearly beneficial in acute MI, its role in stable CAD is less clear; PCI use for stable CAD fell substantially from 2007 to 2011, especially in high-volume PCI hospitals.


To improve survival, CABG is recommended for significant left main stenosis (>50%), proximal LAD stenosis >70%, three-vessel disease with >70% stenosis, or two-vessel disease with severe/extensive ischemia, and for patients with mild-to-moderate LV systolic dysfunction (EF 35%–50%) with significant multivessel CAD. A left internal mammary artery graft to the LAD improves survival. CABG is preferred over PCI to improve survival in multivessel CAD with SYNTAX score >22 and in multivessel CAD with diabetes, particularly when LIMA-to-LAD grafting is used. PCI may be a reasonable alternative to CABG in selected stable patients with unprotected left main CAD when SYNTAX is low-to-intermediate and/or surgical risk is high (e.g., STS operative mortality risk >5%), PCI procedural complication risk is low, and likelihood of good long-term outcome is high.


To improve symptoms, CABG or PCI can be beneficial for patients with one or more significant (>70%) stenoses amenable to revascularization who have unacceptable angina despite maximal medical therapy, or when medications cannot be intensified due to contraindications, adverse effects, or patient preference. The ORBITA trial (2017) showed no significant improvement in angina score after PCI in optimally treated stable angina, though most placebo-group patients later underwent PCI. The ISCHEMIA trial (2020) showed no benefit of routine invasive therapy over conservative treatment in moderate-to-severe ischemia, but excluded patients with acute coronary syndrome, severe/frequent symptoms, EF <35%, and left main stenosis. hybrid revascularization (lima-to-lad grafting plus pci to non-lad vessels) may be used when the aorta is unfavorable, cabg targets are poor, conduits unsuitable, or lad anatomy unfavorable for pci. compared with pci, provides more effective angina relief fewer repeat procedures but carries a higher procedural stroke risk; 10-year survival similar.< />pan>


PCI is widely used for symptom relief but is not superior to intensive medical therapy in preventing MI or death in stable patients. Candidates for PCI should also be candidates for CABG. About 80% experience immediate symptom benefit after PCI. Stents are used in the majority of PCI cases and reduce restenosis when used electively in atheromatous lesions. Key limitations of stenting include subacute thrombosis, in-stent restenosis, bleeding risk from antiplatelet therapy, and higher cost. Dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) prevents stent thrombosis; duration depends on stent type—about 4 weeks for bare metal stents and generally 6–12 months for drug-eluting stents due to delayed endothelialization. Newer drug-eluting stents with thin struts and limus-family drugs from durable polymers reduce stent thrombosis risk compared with early-generation sirolimus- or paclitaxel-eluting stents. Current evidence supports drug-eluting stents in most settings unless dual antiplatelet therapy is contraindicated.


Pearls and Considerations
Although nitrate responsiveness has traditionally been part of the diagnostic approach for stable ischemic heart disease, some evidence suggests that relief after nitroglycerin does not reliably predict active coronary artery disease in general chest pain admissions and should not be used alone to guide acute diagnosis. CABG offers higher long-term survival and fewer repeat revascularizations than PCI in some populations, but many patients prefer stenting because it is less invasive, involves shorter hospitalization, and has lower in-hospital mortality.

KembaraXtra-Medicine – Anaphylaxis




Anaphylaxis is a severe, rapid-onset, life-threatening allergic reaction. It occurs when IgE-mediated and non–IgE-mediated systemic mast cell degranulation leads to release of inflammatory mediators, producing respiratory, cardiovascular, gastrointestinal, and/or mucocutaneous symptoms. A common synonym is anaphylactic reaction. Relevant ICD-10CM codes include T78.2 (anaphylactic shock, unspecified, initial encounter), T78.00XA (anaphylactic reaction due to unspecified food, initial encounter), T80.52XA (anaphylactic reaction due to vaccination, initial encounter), and T63.94XA (toxic effect of contact with unspecified venomous animal, undetermined, initial encounter).


In the United States, the incidence is estimated at 50 to 2000 episodes per 100,000 persons, with a lifetime prevalence of 1.6% to 5.1%. Emergency department visits for anaphylaxis increased by 101% from 2005 to 2014, yet fatalities have remained stable at about 0.7 per million adults per year. In adults, medications and insect stings are leading triggers, while in children and adolescents, foods and insect stings are the leading triggers.


Risk factors depend on the trigger and severity. Atopy increases risk for anaphylaxis triggered by food, exercise, and latex. Risk factors for severe anaphylaxis include cardiovascular disease, asthma, older age, mast cell disorder, beta-blocker use, and ACE inhibitor use.


Clinical presentation commonly includes involvement across multiple systems. Mucocutaneous findings include urticaria, pruritus, flushing, and angioedema. Respiratory symptoms include dyspnea, cough, wheezing, hypoxia, stridor, and rhinitis. Cardiovascular features include hypotension, tachycardia, weakness, dizziness, syncope, malaise, and vascular collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, dysphagia, and abdominal pain.


Anaphylaxis results from a sudden systemic release of histamine and other mediators from basophils and mast cells via IgE-dependent and non–IgE-dependent mechanisms, and almost any substance can trigger it. In acute settings, the cause is often not identified, accounting for 30% to 60% of cases. Common triggers include foods and additives (notably peanuts, tree nuts, eggs, shellfish, fish, cow’s milk, fruits, soy). A notable food-related mechanism is alpha-gal syndrome, where a lone star tick bite can cause IgE sensitization to alpha-1,3-galactose, leading to delayed anaphylaxis after eating mammalian (red meat) products. Medication triggers include antibiotics (especially penicillins and sulfa agents), insulin, allergen extracts, opiates, vaccines, NSAIDs, contrast media, streptokinase, immunomodulators, and IV iron. Environmental exposures include bee/wasp stings, snake venom, and fire ant venom. Other triggers include blood products (plasma, immunoglobulin, cryoprecipitate, whole blood), latex, and exercise. Mechanistically, immune (often IgE-mediated) triggers include foods, venoms, many medications, latex, seminal fluid, and sometimes radiocontrast; IgE-independent immune triggers include radiocontrast (in most cases), dextrans, some monoclonal antibodies (e.g., rituximab), and some medications; and nonimmunologic triggers include certain drugs such as opioids and protamine. “Idiopathic” anaphylaxis refers to cases where known causes (including mastocytosis) have been excluded. Non–IgE mechanisms may involve complement activation, kinin production, potentiation, or direct mediator release, and more than one mechanism can occur together (for example, exercise-induced reactions following food). ACE inhibitors are a notable cause of unexplained angioedema, occurring in up to 1 in 200 users and may occur at any time after starting the medication.


The differential diagnosis is broad and includes allergic reactions without anaphylaxis, other causes of shock such as sepsis or pulmonary embolism, endocrine conditions such as carcinoid, adrenal crisis, paradoxical pheochromocytoma, systemic mastocytosis, serum sickness, severe asthma (distinguished by abrupt onset in anaphylaxis versus progressive worsening), scombroid poisoning, localized angioedema, acute urticaria, vasovagal/presyncopal syndromes, airway foreign body, vocal cord dysfunction, and anxiety-related symptoms such as globus hystericus.


Workup is mainly aimed at excluding mimics, but treatment should never be delayed because anaphylaxis can be rapidly fatal. Diagnosis is primarily clinical. Laboratory testing is generally not helpful in the emergency setting, though serum/urine histamine and serum tryptase (drawn 30 minutes to 2 hours after symptom onset and compared with baseline) may support the diagnosis; importantly, normal levels do not exclude anaphylaxis and these tests may not be readily available. Imaging is usually not helpful; chest radiography is considered when evaluating foreign body aspiration or pulmonary pathology in acute respiratory compromise. An ECG should be considered in patients with sudden loss of consciousness, chest pain, dyspnea, and in elderly patients; ECG typically shows sinus tachycardia.


Clinical criteria make anaphylaxis highly likely when any one of the following is met: (1) an acute illness with skin/mucosal involvement plus either respiratory compromise or reduced blood pressure/end-organ dysfunction symptoms; (2) rapid onset of two or more after exposure to a likely allergen--skin/mucosal involvement, respiratory compromise, reduced blood pressure, or persistent GI symptoms such as crampy abdominal pain/vomiting; or (3) reduced blood pressure after exposure to a known allergen--age-specific hypotension or >30% systolic BP decrease in infants/children, or systolic BP <90 mm hg or>30% decrease from baseline in adults.


Immediate nonpharmacologic treatment begins with removing the trigger, rapidly establishing and protecting the airway, providing supplemental oxygen if needed, obtaining IV access, giving IV fluids (normal saline), and placing the patient on cardiac monitoring.


The cornerstone medication is intramuscular epinephrine. Adults and children >30 kg should receive 0.3 to 0.5 mg IM epinephrine (1:1000 concentration) in the anterolateral thigh; anyone >50 kg should receive 0.5 mg IM. Children <30 kg should receive 0.01 mg />g IM epinephrine (1:1000 concentration). IM administration is preferred because it produces a faster and more reliable rise to effective plasma levels, and the dose can be repeated within minutes if symptoms do not improve. Adjunct therapies include H1 and H2 antihistamines such as diphenhydramine and famotidine to improve itching and erythema, but they do not reverse airway obstruction, respiratory compromise, or hypotension, and their onset is delayed 1–2 hours. Corticosteroids do not help acutely because of slow onset and have not been shown to prevent prolonged or biphasic anaphylaxis, but they are commonly used as secondary treatment. Aerosolized beta-agonists help treat bronchospasm. If hypotension or cardiovascular collapse persists despite fluids and IM epinephrine, IV epinephrine (1:10,000 concentration) is used as vasopressor therapy, and small IV boluses may be used in the peri-arrest state. Patients on beta-blockers may respond poorly to initial treatment; in these cases, IV glucagon should be considered.


Disposition depends on severity and risk of recurrence. Patients with mild episodes should be observed for 1 hour after symptom resolution. Patients with severe symptoms—including cyanosis, pulse oximetry <92%, systolic bp <90 mm hg, confusion, loss of consciousness, or incontinence—those needing more than one epinephrine dose, those with a wide pulse pressure, unknown trigger, cutaneous signs />ymptoms, or a medication trigger in children should be observed for at least 6 hours to watch for biphasic anaphylaxis.


For discharge planning and chronic management, patients who are stable and remain asymptomatic should be prescribed two epinephrine autoinjectors, with clear instructions on when and how to use them. Referral to an allergist is helpful when the trigger is unclear in the emergency setting. Patient education is essential: a prior history of anaphylaxis or known triggers is the most reliable way to identify risk. Patients should be instructed to carry an epinephrine device at all times; school-aged children should have an additional autoinjector available at school with appropriate staff. Patients should also be advised to wear or carry MedicAlert identification listing substances that have triggered anaphylaxis. People with prior contrast reactions should avoid radiologic contrast when possible; however, pretreatment regimens with methylprednisolone or diphenhydramine may be used when contrast is unavoidable. For insect-sting anaphylaxis, venom immunotherapy initiated after the event is effective and is recommended for up to 5 years after the incident.

KembaraXtra-Medicine- Ankle Sprain


Basic Information and Definition
An ankle sprain is an injury involving the ligamentous structures that stabilize the ankle joint. Approximately 85% of ankle sprains affect the lateral ligament complex, most commonly the anterior talofibular ligament (ATFL), followed by the calcaneofibular ligament (CFL). Medial ankle sprains involve the deltoid ligament and are less common but tend to be more severe. High ankle sprains involve injury to the distal tibiofibular syndesmosis, including the anterior inferior tibiofibular ligament, posterior inferior tibiofibular ligament, interosseous membrane, and inferior transverse ligament. Ankle sprains are typically graded as I, II, or III based on the extent of ligament injury and joint stability.


Classification
Grade I sprains involve stretching of the ATFL with mild swelling, tenderness, and no joint instability, and patients are usually able to bear weight. Grade II sprains consist of a tear of the ATFL with a sprain of the CFL, resulting in moderate swelling, tenderness, and mild to moderate instability, often demonstrated by a positive anterior drawer test. Grade III sprains involve complete tears of both the ATFL and CFL, producing severe swelling, marked instability on anterior drawer and talar tilt testing, and inability to bear weight. These injuries may require prolonged immobilization and, in some cases, surgical intervention.


ICD-10-CM Codes
Coding includes sprains of the calcaneofibular ligament, deltoid ligament, or tibiofibular ligament, with specification of laterality, encounter type (initial, subsequent, or sequela), and whether the ankle is right, left, or unspecified.


Epidemiology and Demographics
Ankle sprains are among the most common musculoskeletal injuries, with an estimated prevalence of one case per 10,000 people per day. They are especially common in athletic and physically active populations. There is no clear gender predominance, and incidence varies with age and activity level.


Physical Findings and Clinical Presentation
Patients often report a twisting injury with inversion or eversion and may describe hearing or feeling a “pop” at the time of injury. Examination typically reveals swelling, ecchymosis, and tenderness over the affected ligaments and malleoli. Lateral ankle sprains usually present with pain over the ATFL and CFL, whereas medial sprains cause tenderness over the deltoid ligament. Weight-bearing ability varies with injury severity.


Provocative Testing
The anterior drawer test assesses the integrity of the ATFL by evaluating anterior translation of the talus relative to the tibia. The talar tilt (inversion stress) test evaluates lateral ligament stability, particularly the CFL. Syndesmotic injury is assessed with the squeeze test, in which compression of the tibia and fibula at the mid-calf produces distal ankle pain.


Etiology and Risk Factors
Inversion combined with plantarflexion is the most common mechanism for lateral ankle sprains. Eversion and rotational forces may injure the deltoid ligament or syndesmosis. Risk factors include poor balance, impaired proprioception, and weakness of the peroneal muscles.


Diagnosis
Diagnosis is primarily clinical, based on history and physical examination. Most ankle sprains can be diagnosed without advanced testing, provided fracture and significant instability are excluded.


Differential Diagnosis
The differential includes ankle and foot fractures (including malleolar, talar dome, calcaneal, and fifth metatarsal fractures), Lisfranc injury, Achilles tendon rupture, and peroneal tendon rupture.


Workup and Imaging
Plain radiographs are not routinely required unless fracture is suspected. The Ottawa ankle rules guide imaging decisions and recommend radiographs when there is malleolar or midfoot pain with bony tenderness or inability to bear weight. When indicated, initial imaging includes weight-bearing anteroposterior, lateral, and mortise views. Stress radiographs may be used to assess instability. MRI is reserved for patients with persistent symptoms despite adequate conservative management and may reveal ligament tears, tendon injury, or osteochondral lesions.


Acute Treatment
Initial management follows the PRICE principle: protection with a brace or boot, rest, ice for the first 3 to 7 days, compression, and elevation. Pain control is achieved with NSAIDs or acetaminophen. After the first 48 hours, early controlled motion using a functional ankle brace is encouraged. Short-term immobilization, up to 10 days, may shorten recovery in more severe sprains. Physical therapy is recommended to restore range of motion, improve proprioception, and strengthen supporting musculature. Grade III sprains and syndesmotic injuries with significant instability should be referred for orthopedic evaluation, as surgical management may be required in selected patients.


Chronic Management and Rehabilitation
Rehabilitation focuses on strengthening, balance training, and prevention of reinjury. Lateral heel wedges may reduce hindfoot inversion. Protective taping or bracing is recommended during high-risk activities and should be continued for up to 6 months in patients with grade II or III sprains.


Disposition and Prognosis
Most ankle sprains resolve within 2 to 6 weeks, although residual pain, swelling, or stiffness may persist for months. Syndesmotic injuries typically require longer recovery. Chronic instability is uncommon but may occur in a minority of patients despite appropriate rehabilitation.


Referral
Orthopedic referral is indicated for patients who fail to improve with conservative treatment, those with suspected high ankle sprains, or patients with persistent instability or pain beyond 6 to 8 weeks.


Pearls and Considerations
Delayed recovery should prompt evaluation for occult fractures, talar dome lesions, chronic tendinopathy, peroneal tendon pathology, reflex sympathetic dystrophy, or syndesmotic injury. Repeat imaging, including MRI, may be necessary in refractory cases.


Related Content
Ankle Sprain (Patient Information) and Ankle Fracture (Related Key Topic).

Emergency And Acute Medicine – Inborn Errors Of Metabolism


Basics
Description Inborn errors of metabolism are inherited defects in metabolic pathways that lead to abnormal accumulation or deficiency of metabolites. More than 400 disorders are described, most presenting in infancy or childhood with variable and often nonspecific findings. Incidence ranges from 1:10,000 to 1:200,000 births. Major categories include amino acid disorders, urea cycle defects, organic acidemias, fatty acid oxidation defects, mitochondrial disorders, carbohydrate disorders, lysosomal storage diseases, peroxisomal disorders, and disorders of protein glycosylation. Pathophysiology relates directly to enzymatic or transport defects within metabolic pathways.
Etiology Genetic deficiency of enzymes or membrane transport systems involved in intermediary metabolism.


Diagnosis
Signs and symptoms Presentation may be acute and catastrophic or chronic and indolent. Neonates may initially be asymptomatic or present with hypothermia (mitochondrial defects), hypotonia or hypertonia (peroxisomal disorders), apnea (urea cycle defects, organic acidemias), seizures, vomiting, poor feeding, jaundice, hypoglycemia, dysmorphic features, or coma. Older untreated children may present with failure to thrive, dehydration, recurrent vomiting or diarrhea, food intolerance, lethargy, ataxia, seizures, or developmental delay.
History Review newborn screening results, dietary history, family history, consanguinity, and intercurrent illness.
Physical exam May reveal abnormal odor, altered mental status, tachypnea, dysmorphic facies, cataracts, cardiomyopathy, hepatosplenomegaly, dermatitis, or jaundice.


Essential workup Consider in any child with unexplained neurologic deterioration, persistent vomiting, metabolic acidosis, hypoglycemia, shock unresponsive to resuscitation, or failure to thrive.


Diagnosis tests and interpretation
Lab Bedside glucose, electrolytes, BUN/creatinine, CBC, calcium, liver function tests, bilirubin, coagulation studies, blood gas, lactate, pyruvate, uric acid, urinalysis, ammonia, serum amino acids, urine organic acids, and cultures as indicated.
Imaging CT head for altered mental status; chest radiograph as indicated.
Procedures Lumbar puncture when infection is a concern.


Differential diagnosis Sepsis, meningitis, encephalitis, dehydration, toxic ingestion, nonaccidental trauma, Reye syndrome, hepatic encephalopathy, endocrine disorders, renal failure, renal tubular acidosis, CNS mass lesions.


Treatment
Prehospital Prioritize ABCs and bedside glucose. Start IV glucose immediately; do not delay for fluids unless in shock. Avoid lactated Ringer solution. Keep patient NPO.
Initial stabilization Administer glucose (after Accu-Chek and thiamine when appropriate) and naloxone for altered mental status.
Emergency department management Secure airway, breathing, and circulation. Use normal saline for fluid boluses and avoid hypotonic fluids and lactated Ringer. Initiate IV glucose at 8–10 mg/kg/min (D10 at 1.5× maintenance) to prevent catabolism. Treat severe hypoglycemia with D25 bolus. Correct dehydration and acid–base abnormalities; consider bicarbonate only if pH <7.0. initiate dialysis for refractory severe acidosis or hyperammonemia. stop all oral intake initially. treat hyperammonemia urgently with ammonia-scavenging agents (arginine, sodium benzoate, phenylacetate, phenylbutyrate) in consultation a metabolic specialist. identify and precipitating infections.< />pan>


Medication D25 2–4 mL/kg IV for hypoglycemia, sodium bicarbonate 1–2 mEq/kg IV for severe acidosis, disease-specific therapies such as levocarnitine or pyridoxine as indicated.
First line IV glucose infusion with normal saline as needed for shock.
Second line Bicarbonate therapy for pH <7.0 and hemodialysis when indicated.< />pan>


Follow-up and disposition
Admission criteria All infants and children with suspected inborn errors of metabolism, significant ketosis, inability to tolerate oral intake, altered mental status, severe or persistent acidosis, refractory hypoglycemia, or hyperammonemia; ICU care for severe presentations. Transfer to a specialized pediatric center is often required.
Discharge criteria Normal mental status, adequate hydration, reassuring laboratory results, no significant intercurrent illness, and close follow-up arranged.
Follow-up recommendations Ongoing care with a metabolic disease specialist and primary care physician.


Pearls and pitfalls Always consider metabolic disease in unexplained pediatric decompensation. Do not delay glucose infusion. Avoid lactated Ringer solution. Use bicarbonate cautiously and only for severe acidosis. Early dialysis can be lifesaving in hyperammonemia.

Emergency And Acute Medicine – Impetigo


Basics
Description Impetigo is a common superficial bacterial skin infection. It may be a primary infection of minor skin breaks or a secondary infection of preexisting dermatoses (impetiginization). It is most prevalent in children aged 2–5 years and occurs more often in warm, humid climates and summer months. Predisposing factors include minor trauma (especially around the nose), insect bites, burns, diabetes mellitus, HIV infection, varicella, and chronic skin disease. Complications include acute poststreptococcal glomerulonephritis (1–5% of nonbullous cases), cellulitis, sepsis, endocarditis, toxic shock syndrome, and staphylococcal scalded skin syndrome.


Etiology
Classic (nonbullous) impetigo results from bacterial entry through disrupted skin and is caused by Staphylococcus aureus, group A β-hemolytic streptococci, or both. Bullous impetigo is caused exclusively by S. aureus producing exfoliative toxins (A, B, D) that cleave desmoglein 1, leading to intraepidermal blistering.


Diagnosis
Signs and symptoms Nonbullous impetigo begins as erythematous macules or papules that evolve into vesicles or pustules, which rupture and form characteristic honey-colored crusts. Lesions are highly contagious and often pruritic. Regional lymphadenopathy may occur; systemic symptoms are uncommon. Bullous impetigo presents with flaccid bullae containing clear or yellow fluid that rupture easily, leaving erythematous bases; Nikolsky sign is absent. Fever and systemic symptoms are rare.
Physical exam Lesions most commonly involve the face, extremities, and scalp. Diagnosis is clinical based on appearance and distribution.


Essential workup
Routine laboratory testing is not required. Consider bacterial culture of bullae or pustules for refractory disease, outbreak investigation, or suspected methicillin-resistant S. aureus.


Diagnosis tests and interpretation
Lab Anti–DNase B titers may be elevated in poststreptococcal glomerulonephritis. Urinalysis is indicated if hematuria or edema suggests nephritis.
Imaging and procedures Not routinely indicated; biopsy is rarely necessary.


Differential diagnosis
Herpes simplex, varicella zoster, atopic or contact dermatitis, dermatophytosis, candidiasis, scabies, folliculitis, erysipelas, bullous pemphigoid, pemphigus vulgaris, staphylococcal scalded skin syndrome, Stevens–Johnson syndrome, thermal burns, toxic epidermal necrolysis, and cutaneous anthrax.


Treatment
Prehospital Cover lesions and use universal precautions to prevent transmission.
Initial stabilization Impetigo is rarely life-threatening in otherwise healthy patients.
Emergency department management Local care includes gentle cleansing, removal of crusts, and wet dressings. Small, localized nonbullous lesions may be treated with topical antibiotics alone. Extensive disease, bullous impetigo, lymphadenopathy, systemic symptoms, or outbreak settings require systemic antibiotics. Empiric therapy should cover S. aureus and streptococci; adjust for MRSA based on local resistance patterns.


Medication
Topical (nonbullous only): mupirocin 2% TID for 10 days or retapamulin 1% BID for 5 days.
Oral options (10 days unless noted): amoxicillin–clavulanate, cephalexin, dicloxacillin, clindamycin, azithromycin (5-day course), or trimethoprim–sulfamethoxazole when MRSA suspected. Doxycycline may be used for MRSA in patients ≥8 years.


Follow-up and disposition
Admission criteria Rare; consider for widespread disease, extensive bullae or denuded skin, dehydration, treatment failure, toxic appearance, immunocompromise, or neonates.
Discharge criteria Nontoxic patients with reliable caregivers and ability to comply with therapy.
Follow-up recommendations Primary care follow-up to ensure resolution. Return for lack of improvement or signs of nephritis (hematuria, periorbital or leg edema).


Pearls and pitfalls
Use systemic antibiotics for bullous disease or lymphadenopathy. Rising antibiotic resistance limits older regimens; suspect mupirocin resistance with treatment failure and switch agents. Treat affected household contacts simultaneously to prevent reinfection.